The following article features coverage from the American Society of Clinical Oncology 2019 meeting. Click here to read more of Hematology Advisor’s conference coverage.

Autologous transplantation remains the preferred consolidation therapy for transplant-eligible patients with peripheral T-cell lymphoma (PTCL) compared with allogeneic transplantation.

Researchers presented results from a prospective randomized trial assessing the therapeutic value of autologous and allogeneic transplantation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Patients had newly diagnosed PTCL and received either carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy followed by autologous transplantation (54 patients) or myeloablative conditioning followed by allogeneic transplantation (49 patients).

Event-free survival at 3 years after transplant was the primary endpoint. The study was terminated early after a preplanned interim analysis.

Related Articles

The median observation time was 42 months. In total, 36 patients were unable to undergo transplantation, primarily because of early progression. The rate of event-free survival was 43% for allogeneic transplantation and 38% for autologous transplantation (P =.58). The rate of overall survival was 57% for allogeneic transplantation and 70% for autologous transplantation (P =.41). These rates remained comparable between the 2 cohorts after excluding patients who did not undergo transplant.

In the autologous transplantation cohort, there was no treatment-related mortality, but 13 patients experienced relapse. In the allogeneic transplantation cohort, no patients experienced relapse, but the rate of treatment-related mortality was 31% (8 patients).

The researchers reported differences were seen in event-free, progression-free, and overall survival when patients were stratified by age-adjusted International Prognostic Index score.

Although no significant survival differences were seen between cohorts, the researchers stated that “autologous transplantation remains the preferred consolidation because patients relapsing after autologous transplantation can be successfully salvaged with allogeneic transplantation.”

Reference

1.     Shmitz N, Truemper L, Ziepert M, et al. First-line therapy of T-cell lymphoma: Allogeneic or autologous transplantation for consolidation — Final results of the AATT study. Oral presentation at: 2019 ASCO Annual Meeting; June 4, 2019; Chicago, IL. Abstract 7503.